Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2021

01-03-2021 | Original Article

How to better stratify the risk of differentiated thyroid carcinomas: the key role of radioactive iodine therapy, age, and gender

Authors: Arnoldo Piccardo, Giacomo Siri, Stefano Raffa, Marco Castellana, Luca Foppiani, Gianluca Bottoni, Martina Ugolini, Angelina Cistaro, Ugo Catrambone, Vania Altrinetti, Michela Massollo, Anselmo Arlandini, Luca Giovanella, Manlio Cabria, Pierpaolo Trimboli

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2021

Login to get access

Abstract

Purpose

The risk of relapse of differentiated thyroid carcinomas (DTC) and their indication for radioactive iodine therapy (RAI) are assessed according to ATA risk stratification system principally based on tumor-nodes-metastasis (TNM) staging. However, while establishing the indication for RAI may be a “dilemma,” performing it can improve the risk stratification. We aimed to evaluate whether (1) the stratification of risk of recurrence differs when TNM is considered with or without peri-RAI findings and (2) the assessment of the risk of disease-specific mortality is improved by adding age and gender.

Methods

From our database, all DTC patients treated with thyroidectomy and RAI from 1992 to 2017 were included. Subjects with a follow-up shorter than 1 year and positive thyroid antibodies were excluded. Patients were classified into (1) a three-category ATA model based on TNM (basic model) and (2) a five-category model based on TNM plus peri-RAI findings, i.e., thyroglobulin and 131I whole-body scan (advanced model). Relapse was proven by histology and/or imaging. Differences in disease-free survival (DFS) and overall survival (OS) were assessed.

Results

We enrolled 907 patients; of these, 4.4% died and 21% suffered recurrence. According to the basic model, there were 11.8% high-risk, 32.9% intermediate-risk, and 55.3% low-risk patients. According to the advanced model, 29.9% of patients were re-classified in a higher risk category and the five categories of this model displayed significantly different risks of relapse and death. The estimate of DFS was significantly higher in the advanced model than in the basic one (ΔC-index = + 6.8%, P < .001). By adding age and gender to the advanced model, the highest performance in predicting death was achieved (ΔC-index = + 5.1%, P < .001).

Conclusions

The peri-RAI findings are essential in order to carefully stratify the risk of DTC recurrence. Integrating these data with age and gender enables those cases at highest risk of death to be identified.
Literature
1.
go back to reference Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.CrossRef Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.CrossRef
3.
go back to reference Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid. 2016;26:373–80.CrossRef Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid. 2016;26:373–80.CrossRef
4.
go back to reference Trimboli P, Piccardo A, Signore A, Valabrega S, Barnabei A, Santolamazza G, et al. Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American Thyroid Association stratification system. Thyroid. 2020;30:713–9.CrossRef Trimboli P, Piccardo A, Signore A, Valabrega S, Barnabei A, Santolamazza G, et al. Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American Thyroid Association stratification system. Thyroid. 2020;30:713–9.CrossRef
5.
go back to reference Zahedi A, Bondaz L, Rajaraman M, Leslie WD, Jefford C, Young JE, Pathak KA, Bureau Y, Rachinsky I, Badreddine M, De Brabandere S, Fong H, Maniakas A, Van Uum S. 2019 Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation [Online ahead of print]. Thyroid. doi:https://doi.org/10.1089/thy.2018.0775. Zahedi A, Bondaz L, Rajaraman M, Leslie WD, Jefford C, Young JE, Pathak KA, Bureau Y, Rachinsky I, Badreddine M, De Brabandere S, Fong H, Maniakas A, Van Uum S. 2019 Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation [Online ahead of print]. Thyroid. doi:https://​doi.​org/​10.​1089/​thy.​2018.​0775.
6.
go back to reference Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:1440–5.CrossRef Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:1440–5.CrossRef
7.
go back to reference Piccardo A, Arecco F, Morbelli S, Bianchi P, Barbera F, Finessi M, et al. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer. J Endocrinol Investig. 2010;33:83–7.CrossRef Piccardo A, Arecco F, Morbelli S, Bianchi P, Barbera F, Finessi M, et al. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer. J Endocrinol Investig. 2010;33:83–7.CrossRef
8.
go back to reference Piccardo A, Arecco F, Puntoni M, Foppiani L, Cabria M, Corvisieri S, et al. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival. Clin Nucl Med. 2013;38:18–24.CrossRef Piccardo A, Arecco F, Puntoni M, Foppiani L, Cabria M, Corvisieri S, et al. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival. Clin Nucl Med. 2013;38:18–24.CrossRef
9.
go back to reference Barrack F, Scuffham J, McQuaid S. Septal penetration correction in I-131 imaging following thyroid cancer treatment. Phys Med Biol. 2018;63(7):075012.CrossRef Barrack F, Scuffham J, McQuaid S. Septal penetration correction in I-131 imaging following thyroid cancer treatment. Phys Med Biol. 2018;63(7):075012.CrossRef
10.
go back to reference Newson RB. Comparing the predictive powers of survival models using Harrell’s C or Somers’ D. Stata J. 2010;10:339–58.CrossRef Newson RB. Comparing the predictive powers of survival models using Harrell’s C or Somers’ D. Stata J. 2010;10:339–58.CrossRef
11.
go back to reference Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29:461–70.CrossRef Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019;29:461–70.CrossRef
Metadata
Title
How to better stratify the risk of differentiated thyroid carcinomas: the key role of radioactive iodine therapy, age, and gender
Authors
Arnoldo Piccardo
Giacomo Siri
Stefano Raffa
Marco Castellana
Luca Foppiani
Gianluca Bottoni
Martina Ugolini
Angelina Cistaro
Ugo Catrambone
Vania Altrinetti
Michela Massollo
Anselmo Arlandini
Luca Giovanella
Manlio Cabria
Pierpaolo Trimboli
Publication date
01-03-2021
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-020-05020-5

Other articles of this Issue 3/2021

European Journal of Nuclear Medicine and Molecular Imaging 3/2021 Go to the issue